Rubius Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Rubius Therapeutics

10/05/2021 18:45

* Rubius Therapeutics Inc  RUBY.OQ  reported a quarterly
adjusted loss of 51 cents​​ per share for the quarter ended
in March. The mean expectation of six analysts for the quarter
was for a loss of 52 cents per share.
* Revenue was $0.00​​;  analysts expected $0.00.
* Rubius Therapeutics Inc's reported EPS for the quarter was a
loss of 51 cents​.
* The mean earnings estimate of analysts had fallen by
about 3.3% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Rubius Therapeutics Inc shares had fallen by 1.3% this
quarter and gained 244.5% so far this year.
* The company reported a quarterly loss of $42.33 million.
* Wall Street's median 12-month price target for Rubius
Therapeutics Inc is $32.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
This summary was machine generated May 10 at 05:45 p.m. GMT.
​All figures in $